Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23723295 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
Conditions: Neoplasms;   Prostatic Neoplasms
Interventions: Drug: cabazitaxel (XRP6258) (RPR116258);   Drug: mitoxantrone;   Drug: prednisone

Indicates status has not been verified in more than two years